PMID- 35691258
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20220706
IS  - 1873-6947 (Electronic)
IS  - 1744-3881 (Linking)
VI  - 48
DP  - 2022 Aug
TI  - Efficacy of a standardized herbal product from Pistacia atlantica subsp. Kurdica 
      in type 2 diabetic patients with hyperlipidemia: A triple-blind randomized 
      clinical trial.
PG  - 101613
LID - S1744-3881(22)00081-0 [pii]
LID - 10.1016/j.ctcp.2022.101613 [doi]
AB  - BACKGROUND: Hyperlipidemia is one of the consequences of type 2 diabetes mellitus 
      (T2DM) that puts the patients at the risk of getting cardiovascular disease. 
      Pistacia atlantica subsp. Kurdica is used by local people for the improvement of 
      lipid and glucose indices. This study was carried out to evaluate clinical 
      effects of P. atlantica subsp. Kurdica on hyperlipidemia related to T2DM 
      patients. MATERIALS AND METHODS: In this randomized, triple-blind, and 
      placebo-controlled study, type 2 diabetes patients with hyperlipidemia were 
      randomly allocated to receive either P. atlantica kurdica or placebo capsule for 
      2 months. 58 Patients were followed up at the beginning and after the end of each 
      month for assessment of lipid profiles, glucose indices, and liver and renal 
      function tests. The herbal capsule was standardized according to volatile and 
      nonvolatile compounds by GC-MS/FID and RP-HPLC-PDA, respectively. The total 
      phenolic and flavonoid contents were also determined with a spectrophotometer. 
      RESULTS: After 1 and 2 months of the intervention period, mean differences of 
      2HPP, total cholesterol, and LDL-c have been reduced significantly (P < 0.05) 
      between the two groups, but there were not reported any significant statistical 
      changes in FBS, HbA1c, TG, HDL-c, ALT, AST, and Cr. The herbal capsule was 
      standardized according to benzoic acid, ballic acid, rutin, and quercetin 
      standard (6.5, 2.1, 1.4, 0.7 mg, respectively), and also alpha-pinene as major 
      volatile constituent 28.51%. CONCLUSION: According to results the P. atlantica 
      kurdica is effective in the improvement of lipid profile and glucose indices in 
      line with its local application. CLINICAL TRIAL ID: (IRCT201708109014N178).
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Majd, Faezeh Safari
AU  - Majd FS
AD  - Department of Pharmacognosy, School of Pharmacy, Medicinal Plants and Natural 
      Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
FAU - Talebi, Seyed Saman
AU  - Talebi SS
AD  - Department of Internal Medicine, School of Medicine, Hamadan University of 
      Medical Sciences, Hamadan, Iran.
FAU - Ahmad Abadi, Amir Nili
AU  - Ahmad Abadi AN
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Medicinal Plants 
      and Natural Products Research Center, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Poorolajal, Jalal
AU  - Poorolajal J
AD  - Department of Epidemiology, School of Public Health, Hamadan University of 
      Medical Sciences, Hamadan, Iran.
FAU - Dastan, Dara
AU  - Dastan D
AD  - Department of Pharmacognosy, School of Pharmacy, Medicinal Plants and Natural 
      Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. 
      Electronic address: d.dastan@umsha.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220608
PL  - England
TA  - Complement Ther Clin Pract
JT  - Complementary therapies in clinical practice
JID - 101225531
RN  - 0 (Lipids)
RN  - IY9XDZ35W2 (Glucose)
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucose/therapeutic use
MH  - Humans
MH  - *Hyperlipidemias/drug therapy
MH  - Lipids
MH  - *Pistacia
OTO - NOTNLM
OT  - Diabetes
OT  - Herbal standardization
OT  - Hyperlipidemia
OT  - P. atlantica subsp. Kurdica
OT  - Phytochemical
EDAT- 2022/06/13 06:00
MHDA- 2022/07/07 06:00
CRDT- 2022/06/12 18:18
PHST- 2022/03/02 00:00 [received]
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/05/29 00:00 [accepted]
PHST- 2022/06/13 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
PHST- 2022/06/12 18:18 [entrez]
AID - S1744-3881(22)00081-0 [pii]
AID - 10.1016/j.ctcp.2022.101613 [doi]
PST - ppublish
SO  - Complement Ther Clin Pract. 2022 Aug;48:101613. doi: 10.1016/j.ctcp.2022.101613. 
      Epub 2022 Jun 8.